If successful, a new drug from the biotech Myovant Sciences Ltd. could treat two womens health disorders, as well as prostate cancer.
The drug, Relugolix, works to reduce estrogen in women and testosterone in men. The hormones are factors in two painful conditions affecting women, uterine fibroids and endometriosis, and in prostate cancer.
Treating those conditions with a hormone-blocking medication is not completely new AbbVie Inc.s
Lupron Depot, for example, already does it. But that drug has to be injected, has safety issues and is not supposed to be used in the long term, said Leerink Partners analyst Jason Gerberry. The uterine fibroids and endometriosis markets are both large, but there are no effective, well tolerated oral therapies for them, he said.